FDA approves Wellbutrin XL(TM)( rated bioequivalence to both. At doses...),Health

rated bioequivalence to both. At doses of up to 300 mg/day of the sustained-release formulation (Wellbutrin SR), the incidence of seizure is approximately 0.1 percent. At doses of 300 mg/day to 450 mg/day of the immediate-release (Wellbutrin), the incidence of seizure is approximately 0.4 percent. To reduce the risk of seizures, refer to the Warnings section of the Prescribing Information for patient selection considerations, including concomitant medications and dosing recommendations.

The weight loss potential of Wellbutrin XL should be considered if weight loss is a major presenting sign of the depressive illness.

When treating patients with severe hepatic cirrhosis, extreme caution should be exercised and a reduced dosage and/or frequency is required to avoid accumulation.

ABOUT GLAXOSMITHKLINE

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GlaxoSmithKline has U.S. operations in Philadelphia and Research Triangle Park, N.C.

'"/>

Contact: Holly Russell
919-483-2839
Cooney Waters Group, Inc.
29-Aug-2003

Page: 1 2 3 4
Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves new labelling for Seroquel in bioplar mania
7. FDA approves Enbrel to treat psoriasis
8. FDA approves Climara Pro to treat menopause symptoms
9. FDA approves new approach to schizophrenia treatment
10. FDA approves new HIV protease inhibitor, Lexiva (TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A